NeoGenomics (MEX:NEO) Other Current Liabilities: MXN-3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
73 GF Score
Price MXN176.40
GF Value MXN168.73
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Other Current Liabilities?

NeoGenomics MEX:NEO 73 Other Current Liabilities is MXN-3 Mil as of Jun. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 73/100 and a GF Value™ of MXN168.73. The stock has 6 warning signs investors should review.

NeoGenomics's other current liabilities for the quarter that ended in Jun. 2026 was MXN-3 Mil.

NeoGenomics's quarterly other current liabilities declined from Dec. 2025 (MXN857 Mil) to Mar. 2026 (MXN732 Mil) and declined from Mar. 2026 (MXN732 Mil) to Jun. 2026 (MXN-3 Mil).

NeoGenomics's annual other current liabilities increased from Dec. 2023 (MXN902 Mil) to Dec. 2024 (MXN1,302 Mil) but then declined from Dec. 2024 (MXN1,302 Mil) to Dec. 2025 (MXN857 Mil).

NeoGenomics Other Current Liabilities Related Terms

NeoGenomics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Other Current Liabilities Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 785.77 782.59 902.37 1,302.29 856.71

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 922.88 949.85 856.71 731.70 -3.39
MEX:NEO
73GF Score
NeoGenomics Inc MEX:NEO
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN-3 Mil mean?
NeoGenomics (MEX:NEO) has a Other Current Liabilities of MXN-3 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on NeoGenomics.
Is NeoGenomics' Other Current Liabilities too high?
NeoGenomics' current Other Current Liabilities is MXN-3 Mil. Overall, NeoGenomics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Other Current Liabilities compare to WGS and CDNA?
NeoGenomics' Other Current Liabilities of MXN-3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on NeoGenomics. NeoGenomics's current Other Current Liabilities is MXN-3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
NeoGenomics (MEX:NEO) has a current Other Current Liabilities of MXN-3 Mil. The stock's GF Value™ is MXN168.73, compared to a current price of MXN176.40 — trading 4.5% above its estimated fair value. The current Other Current Liabilities is MXN-3 Mil. NeoGenomics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Other Current Liabilities is MXN-3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be overvalued. The current stock price of MXN176.40 is trading 4.5% above its estimated GF Value™ of MXN168.73.

Key valuation signals for MEX:NEO:

  • Other Current Liabilities: MXN-3 Mil
  • GF Value™: MXN168.73 vs. price of MXN176.40 (4.5% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
73GF Score

Get the complete analysis for MEX:NEO

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN168.73
GF Value